Fig. 2: Combination of chidamide and duvelisib inhibits tumor growth in a p53-mutant DLBCL xenograft model. | Cell Death Discovery

Fig. 2: Combination of chidamide and duvelisib inhibits tumor growth in a p53-mutant DLBCL xenograft model.

From: Combination of HDAC inhibitor and PI3K inhibitor suppresses autophagy and induces apoptosis via cytoplasmic IκBα stabilization in p53-mutant diffuse large B-cell lymphoma

Fig. 2

A p53+ DLBCL tumor xenograft mouse model was established using TMD8 cells (A). Daily oral gavage administration with chidamide, duvelisib, or their combination was initiated post-tumor formation. Mouse body weight (B) and tumor volume (F) were measured daily. E Subcutaneous tumors were excised and photographed at experimental endpoint, with intergroup comparisons of tumor weight (C) and volume (G) for efficacy evaluation. Liver, kidney, and tumor tissues were fixed for hematoxylin-eosin (HE) staining(H). Immunohistochemical detection of Ki67 and PCNA expression was performed to assess tumor cell proliferation in vivo (I–K). Tumor cell apoptosis was evaluated by TUNEL staining (L). Kaplan-Meier overall survival (OS) curve of xenograft mice (D). Data are presented as mean ± SD analyzed by one-way ANOVA, with *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.

Back to article page